Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01479413|
Recruitment Status : Completed
First Posted : November 24, 2011
Last Update Posted : September 11, 2013
The investigators will investigate
- the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome.
- the relationships between aberrant mitochondria genes (single nucleotide polymorphism of D-loop region-related genes and haplogroup N9a), DISC1 gene polymorphism, and clinical phenotypes in Taiwanese populations.
- whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.
|Condition or disease|
In past study, we had shown that there were significant differences in serum Lpo (lipid peroxidation) and Thiol levels between patients with schizophrenia and healthy controls. For patients taking risperidone, there were significant decreases in serum Thiol levels. In addition, there were also significant differences in age of onset of PPAR gamma coactivator 1α (PGC-1α) polymorphism for schizophrenia patients. Therefore, we want to know the relationships between oxidative stress-, apoptosis-related markers, mitochondria DNA copy numbers and the clinical psychopathology of schizophrenia, including severity of positive and negative symptoms, obesity and metabolic syndrome.
In past study, we also found that there were significant differences in 10 SNPs located in the D-loop region-related genes between patients and healthy controls. Three SNPs could be found in Mitomap data, but another seven SNPs not been found in the Mitomap and they could be more confirmed. In addition, Tanaka et al. found that haplogroup N9a was related to diabetes and metabolic syndrome in Asia. Therefore, we were interested to clarify the relationships between above related mitochondria genes and clinical phenotypes in Taiwanese populations,.
In addition, we also want to see whether these biological markers could be as clinical markers in schizophrenia for a long-term follow-up study.
|Study Type :||Observational|
|Actual Enrollment :||77 participants|
|Official Title:||Mitochondria and Schizophrenia: Effects of Antipsychotic Drugs|
|Study Start Date :||August 2009|
|Actual Primary Completion Date :||July 2012|
|Actual Study Completion Date :||September 2013|
- Serum oxidative stress [ Time Frame: 15 months ]serum malondialdehyde (MDA) content, serum free thiols, serum glutathione, catalase, Superoxide dismutase, glutathione peroxidase, proapoptotic markers (bad and bax) and antiapoptotic markers (bcl-2 and bcl-x1), quantification of mitochondrial DNA
- DISC1 gene polymorphism [ Time Frame: 15 months ]
- PANSS score [ Time Frame: 15 months ]Positive and Negative Syndrome Scale to reflect the severity of psychopathology
- Obesity [ Time Frame: 15 months ]obesity defined by body mass index (BMI)>=26.4
- Metabolic syndrome [ Time Frame: 15 months ]
- Drug response [ Time Frame: 15 months ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01479413
|Department of Psychiatry, Chang Gung Memorial Hospital|
|Principal Investigator:||Tiao-Lai Huang, M.D.||Chang-Gung Memorial Hospital, Kaohsiung|